Hudson Bay Capital Management
JUNO

Hudson Bay Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Hudson Bay Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-70,000
Closed -$3.14M – 600
2017
Q3 		$3.14M Sell
70,000
-30,000
-30% -$1.02M 0.08% 199
2017
Q2 		$2.99M Hold
100,000
– – 0.06% 278
2017
Q1 		$2.22M Buy
+100,000
New +$2.14M 0.03% 439

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Hudson Bay Capital Management's JUNO Position: Q4 2017 in Review

Hudson Bay Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 70,000 shares — an estimated $3.14M sold.

Hudson Bay Capital Management first reported a position in JUNO in Q1 2017 and held it in 3 quarters. The position peaked at $3.14M in Q3 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Hudson Bay Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Hudson Bay Capital Management sold 70,000 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $3.14M.
  • Hudson Bay Capital Management first reported a position in Juno Therapeutics, Inc. in Q1 2017 and held it in 3 quarters.
  • Hudson Bay Capital Management's Juno Therapeutics, Inc. position peaked at $3.14M in Q3 2017.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Hudson Bay Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.